Jim Cramer is bullish on Philip Morris, 3M and Becton Dickinson; but he's bearish on Blue Apron and Puma Biotechnology.
Jim Cramer says history doesn't have to repeat itself. You don't want to miss another opportunity in the highly visible FANG-style stocks.
In the U.S., one in eight women will be diagnosed with breast cancer in their lifetime; for men, the risk is one in 1,000.
Puma Biotechnology, Nektar Therapeutics and Paratek Pharmaceuticals were among the biotech movers in premarket trading on July 18.
Comey's testimony? U.K. elections? Eurozone news? These can be new buying opportunities, says Jim Cramer.